6,678 trials
Influenza · Orthomyxoviridae Infections
Primary: Number of Participants With Solicited Local and Systemic Reactions After Fluzone® Vaccination 1 — 10; 2; 2; 1 Participants
Contraception
Primary: Maximum Concentration (Cmax) (Pharmacokinentic Parameter (PK)) for All Subjects in the Pharmacokinetically Evaluable (ASPE) Group — 168; 105; 37.1 pg/ml
Bacterial Conjunctivitis
Primary: Exploratory Outcomes From Digital Photography — 17; 7 Participants
Osteoarthritis
Primary: Average Daily Pain Scores - BS11 Pain Scores. — 3; 3 Box Scale 11 boxes
Patient Indicated for an ICD
Primary: Home Monitoring Effectiveness — 2.1; 3.8 In-office ICD follow-up per patient year — p=<0.001
Asthma
Primary: Change in Mean of Total Score of Asthma Control Questionnaire (ACQ) — -0.76; -0.37 points on a scale — p=<0.0001
Atrial Fibrillation
Primary: Incidence of Atrial Fibrillation Requiring Treatment — 9; 21 participants — p=0.02
Memory Impairment
Primary: Change From Baseline in Neuropsychological Computerized Test — 3.16; -2.38; 1.88; 4.50 Points on a scale
Asthma
Primary: Change From Baseline in the Average AM Peak Expiratory Flow (PEF) Over the 7 Days of Week 8. — 361.8; 374.3; 348.4; 6.03 liters/minute — p=0.654
Stage II Hypertension
Primary: Changes in Mean Sitting DBP From Baseline After 4 Weeks of Therapy — -17.0; -14.1 mmHg
Asthma
Primary: Number of Severe Asthma Exacerbations Per Participant. — 0.097; 0.080 Severe exacerbations per participant
Smoking
Primary: Continuous Abstinence at End of Treatment (Self-report)(Defined as the Number of Consecutive Days Without Smoking a Cigarette for Each Subject) — 83; 75 Participants
Nocturnal Vasomotor Symptoms
Primary: Mean Change in Average Frequency of Awakenings Due to Sleep-time Hot Flashes — -19.54; -20.55; -15.99 Awakenings
Visual Function
Primary: Uncorrected Visual Acuity (UCVA) — 0.06; 0.14 logMAR
Cataract
Primary: Uncorrected Visual Acuity (UCVA) — 0.05; -0.07; 0.15; 0.20 logMAR